TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 173,800 shares, a decrease of 27.6% from the January 15th total of 240,200 shares. Based on an average daily volume of 289,900 shares, the short-interest ratio is presently 0.6 days. Approximately 1.5% of the company’s stock are short sold.
TherapeuticsMD Stock Performance
TXMD opened at $1.03 on Friday. TherapeuticsMD has a twelve month low of $0.70 and a twelve month high of $2.75. The company’s 50-day moving average price is $1.10 and its two-hundred day moving average price is $1.43.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of TherapeuticsMD in a research report on Tuesday, January 14th. They issued a “hold” rating for the company.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
See Also
- Five stocks we like better than TherapeuticsMD
- Business Services Stocks Investing
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- 5 Top Rated Dividend Stocks to Consider
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What Does Downgrade Mean in Investing?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.